Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ELOX
ELOXX PHARMACEUTICALS, INC.
NASDAQ
$15.07
▼ DOWN 5.81% (-0.93)

KEY STATISTICS

Market Cap$51.79 M
52w High$23.40
52w Low$8.20
Dividend Yield—
Frequency—
P/E-0.36
Volume32.10K
Shares Out.3.44M

COMPANY

LEADERSHIP

Sumit Aggarwal
CHIEF EXECUTIVE
Sumit Aggarwal

COMPENSATION 2026

Salary$575,050
Stock Awards$0
Incentive Plan Pay$253,022
All Other Comp.$11,600
Total$1,395,942

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 9, 2026
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
10

PRICE TARGET

Target High$43.00
Target Low$38.00
Target Median$40.50
Target Consensus$40.50

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2026-06-01Reverse1:11
2022-12-02Reverse1:40
2017-12-20Reverse1:20
2013-10-21Reverse1:100
1999-10-25Forward2:1

PRICE

$15.07 ▼ DOWN 5.81% (−$0.93)
OVERLAYS
$15.00$15.75$16.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM15.07

About Eloxx Pharmaceuticals, Inc.

https://www.eloxxpharma.com ↗

Eloxx Pharmaceuticals, founded in 2013 in Watertown, MA, develops ribosome modulation therapies for rare genetic diseases, with lead candidate ELX-02 in Phase 2 trials for cystic fibrosis and nephropathic cystinosis.

INDUSTRY

Biotechnology

A PRODUCT ELOXX PHARMACEUTICALS, INC. IS KNOWN FOR

Exaluren (formerly ELX-02)
Exaluren (formerly ELX-02)

Exaluren, Eloxx Pharmaceuticals' lead investigational drug in Phase 2b trials, targets rare genetic kidney diseases like Alport syndrome and ADPKD caused by nonsense mutations.

COMPETITORS

COMPETITOR
CRSP COMPARE
PTCT COMPARE
RARE COMPARE
SRPT COMPARE
VRTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
1
RANKED BY POSITION SIZE
VTS.AX
0.00% · 57.5K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
10 PERCENT OWNER
Domicilium Real Estate Fund III LP
Purchase · 238.4K shares
2026-06-10
★
10 PERCENT OWNER
Domicilium Real Estate Fund III LP
Purchase · 361.6K shares
2026-06-10
★
10 PERCENT OWNER
Domicilium Real Estate Fund III LP
Purchase · 238.4K shares
2026-06-10
★
10 PERCENT OWNER
Domicilium Real Estate Fund III LP
Purchase · 361.6K shares
2026-06-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY